Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 295-442-6
CAS number: 92045-60-8
A complex combination of hydrocarbons obtained by subjecting a petroleum naphtha to a sweetening process to convert mercaptans or to remove acidic impurities. It consists of hydrocarbons having carbon numbers predominantly in the range of C4 through C5, predominantly C5, and boiling in the range of approximately minus 10°C to 35°C (14°F to 95°F).
28-day repeated dose toxicity, dermal - Systemic NOAEL= 5 ml/kg, or approximately 3750 mg/kg (OECD TG 410 under occlusive conditions)
28-day repeated dose toxicity, inhalation - Systemic NOAEC=2050 ppm, or approximately 9840 mg/3 (OECD TG 412)
90-day repeated dose toxicity, inhalation - Systemic NOAEC>20,000 mg/m3. Local NOAEC = 10,000 mg/m3 (OECD TG 413).
Chronic toxicity, inhalation - Systemic NOAEC=292 ppm, or approximately 1400 mg/m3 (OECD 453)
Repeated exposure of rats by inhalation to unleaded gasoline and naphtha
blending stocks produced very minor effects and only at the highest
levels tested (20,000 – >30,000 mg/m3, depending on
the specific levels tested). Typically the highest levels used in these
tests are limited by safety consideration related to fire and explosion
hazards. The various reported changes at the highest levels included
body weight effects, organ weight changes, variations in hematologic
parameters, and red nasal discharge although not all effects were found
in all studies. The only pathological findings reported were changes in
male rat kidneys associated with alpha-2u-globulin-induced renal
nephropathy. When animals were held without treatment prior to sacrifice
(i.e., recovery groups), the majority of these changes disappeared. In a
study of unleaded gasoline in monkeys, no toxicologically important
findings were apparent at the highest exposure level tested
(approximately 7400 mg/m3). The data from the naphtha
blending stocks are very consistent with the data from gasoline itself.
The dermal studies indicate that gasoline has a very low potential for
systemic toxicity as a consequence of dermal administration. However,
repeated treatment at high levels can produce quite severe dermal
effects at the application site.
Justification for selection of repeated dose toxicity via oral route - systemic effects endpoint:
one of 5 studies investigating the nephrotoxic potential of light hydrocarbons. Alpha 2 u globulin induced nephropathy in the male rat is not a relevant health effect for humans
Justification for selection of repeated dose toxicity inhalation - systemic effects endpoint:
One of 22 studies investigating repeat dose toxicity following inhalation exposure for periods up to 2 yrs. The only consistent effect was alpha 2u nephropathy in male rats, an effect which is not relevant for human health.
Justification for selection of repeated dose toxicity dermal - systemic effects endpoint:
Chronic dermal mouse study, support by 49 other repeat dose dermal studies in rats and mice covering sub-acute and sub-chronic exposure.
Many of the studies described in this section followed regulatory
guidelines and many have been published in the scientific literature.
The data are sufficient for regulatory purposes, no additional testing
is necessary. According to EU CLP regulation (EC No. 1272/2008), the
classification for systemic toxicity is not warranted.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again